Ophthalmology

New AAO 2022 data show the novel treatment administration may eventually save patients money versus standard anti-VEGF injfections.

New findings show the investigative single-dose agent is safe and associated with reduced rescue-dose anti-VEGF treatment.

Comparison of 12- and 24-month regimens of common nAMD treatment show little difference in the common adverse event in patient eyes.

GATHER2 reports a 14.3% reduction in mean rate of growth in GA area over 12 months with avacincaptad pegol compared to sham.

The 3-D technology was able to produce custom frames with a successful fit for patients with craniofacial anomalies at risk of vision loss.

A novel biomarker was identified for posterior uveitis that postulates previously undetected sources of green and red emission fluorescent components (GEFC/REFC).

Serum total cholesterol, HDL-C, and LDL-C were associated positively with IOP, while triglyceride levels may be associated negatively.

The strongest risk factor for RVO was identified as nonideal blood pressure, followed by nonideal body mass index.

Research on the links between AMD and sleep dysfunction is limited but suggests a bidirectional relationship, a systematic review found.

Nonsegmental vitiligo not only affects the skin but can destroy melanocytes in other areas of the body including the eye, new research shows.

Pegcetacoplan treatment effect accelerated between months 18-24 at reducing GA lesion growth in phase 3 DERBY and OAKS.

Hybrid visits were primarily for glaucoma (45.1%) and retinal issues (53.1%).

Whole genome sequencing suggests both common and rare variants contribute to early onset drusen maculopathy.

Pharmacovigilance studies sifting through FDA adverse event reports confirm ocular side effects from PCSK9 inhibitors are infrequent and minor.

Data suggest eyes with a higher ratio of drops taken versus prescribed were significantly more likely to achieve target IOP at 6 months or 1 year.

No advantage was associated with blue light-filtering IOLs in terms of risk of all-cause or traffic-related injury and comfort with driving.

Data suggest most patients who receive a new diagnosis of PACG in the United States do not have a prior diagnosis of anatomical narrow angle.

Significant rapid improvement were observed in both signs and symptoms of thyroid eye disease at week 6 after 2 infusions of 10mg/kg VRDN-001.

Functional and anatomical improvements with aflibercept treatment were obtained at week 24 and persisted until week 52.

Data show foveal thickness fluctuation was significantly associated with logMAR BCVA and the defect length of the foveal EZ band.

Both a higher self-reported water intake and a greater measured 24-h urine volume were tied to an increased DED prevalence.

However, 82% of patients with proliferative diabetic retinopathy at year 2 of the RECOVERY trial demonstrated an improvement in DRSS levels from baseline.

President and CSO of Odylia Therapeutics discusses the gene therapy pipeline, research and differences in operating as a nonprofit biotech company.

Dr Peter Kaiser shares helpful hints for patient communication and for including biosimilars in clinical practice.

An ophthalmologist discusses challenges and concerns that physicians might face when using biosimilars for retinal diseases.